ArticleKidney international reports2025
Clinical Spectrum and Outcome of Kidney Involvement in Non-Langerhans Histiocytosis.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to describe the clinical features and treatment responses of Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) with kidney involvement. Methods: We retrospectively analyzed patients with RDD and ECD with kidney involvement from 2005 to 2023, evaluating kidney function changes, as well as computed tomography (CT), and metabolic responses. Results: The study included 4 patients with RDD and 44 with ECD, with median ages of 58 and 51 years, respectively. Patients with RDD lacked kidney symptoms, whereas 27.3% of patients with ECD exhibited lower extremity edema. The median estimated glomerular filtration rate (eGFR) was 80.5 (63-125) in RDD and 100 (22-133) ml/min per 1.73 m Conclusion: We described details of kidney involvement characteristics and treatment responses in RDD and ECD, highlighting the typical renal mass in RDD and perirenal soft tissue in ECD. Patients with ECD may experience irreversible kidney dysfunction, indicating the critical need for early diagnosis and timely treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.